Recorded January 25, 2023 | On-Demand Webinar
The Inflation Reduction Act (IRA) was signed into law on August 16, 2022. This groundbreaking law requires that HHS Secretary negotiate pricing for certain Medicare covered drugs and manufacturers pay annual rebates to Medicare for price increases above a set threshold. It additionally eliminates enrollee cost sharing for certain vaccines, sets a $35 limit on enrollee cost sharing for insulin, expands premium tax credit eligibility and amount, and eliminates the eligibility phaseout for households with annual incomes above 400% of the federal poverty level, among other provisions. This session will explore these multi-faceted implications of IRA on industry and the state of public health, as well as benefits and risks posed by implementing this framework, including impacts on prescription drug affordability, product hopping, strategy shifting related to patent prosecution, patent litigation, product launching, and federal funding for drug research.